rTMS Treatment for Positive and Negative Symptoms of Schizophrenia

Last updated: April 18, 2019
Sponsor: St. Joseph's Healthcare Hamilton
Overall Status: Active - Recruiting

Phase

2/3

Condition

Tourette's Syndrome

Mood Disorders

Psychosis

Treatment

N/A

Clinical Study ID

NCT03413527
3864
  • Ages 18-75
  • All Genders

Study Summary

This study will examine the effects of rTMS on the negative and positive symptoms of schizophrenia using 2 treatments in sequence applied to related brain areas.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. are voluntary and competent to consent to treatment

  2. have a diagnosis of schizophrenia or schizoaffective disorder

  3. are between the ages of 18 and 75

  4. are willing and able to adhere to the treatment schedule

  5. Pass the TMS adult safety-screening (TASS) questionnaire

  6. have normal thyroid functioning based on pre-study blood work. Patients may bereassessed for the study once thyroid levels have normalized.

  7. are willing and able to cooperate with interviews and follow simple instructions

Exclusion

Exclusion Criteria:

  1. do not pass the TASS Safety Screening Questionnaire

  2. have a significant history of seizures

  3. have active suicidal intent

  4. are pregnant or may be pregnant. A pregnancy test will be performed for fertile women.

  5. have failed a course of Electroconvulsive Therapy (ECT) in the current or previousepisode

  6. have any significant neurological disorder or insult including, but not limited to:any condition likely to be associated with increased intracranial pressure, spaceoccupying brain lesion, any history of seizure except those therapeutically induced byECT, cerebral aneurysm, Parkinson's disease, Huntington's chorea, multiple sclerosis,or head trauma resulting in loss of consciousness greater than or equal to 5 minutes

  7. have an intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlearimplants, or electrodes) or any other metal object within or near the head, excludingthe mouth, that cannot be safely removed

  8. have had changes in dose or initiation of any psychotropic medication in the 4 weeksprior to screening. Patients may be re-screened once medications have been stable for 4 weeks.

  9. currently (or in the last 4 weeks) take more than lorazepam 2 mg daily (or equivalent)or any dose of an anticonvulsant due to the potential to limit rTMS efficacy

Study Design

Total Participants: 20
Study Start date:
February 01, 2016
Estimated Completion Date:
February 29, 2020

Connect with a study center

  • St. Joseph's Healthcare Hamilton

    Hamilton, Ontario L8N3K7
    Canada

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.